I'll research UNH thoroughly before writing the preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent quarter's transcript and release, plus gather more context.I have strong detail on Q1 2026. Let me now get the stock price trajectory, recent news/analyst sentiment, and the year-ago Q2 2025 base for comparison.I now have a comprehensive picture. Let me write the earnings preview.
UNH heads into Q2 as one of the most closely-watched stories in large-cap healthcare — not because of growth, but because of a credibility rebuild. The stock cratered from roughly $600 in April 2025 to a low near $238 in August 2025 amid a Q1 2025 miss, the mid-2025 suspension of guidance, an abrupt CEO change (Stephen Hemsley returning to the helm), a reported DOJ investigation into Medicare practices, and a Q4 2025 that included a ~$3B Optum Health restructuring charge that pushed consolidated operating earnings to just $0.4B.
Since then, shares have staged a substantial recovery, closing at $418.56 on July 15, 2026 — up roughly 24% year-to-date in 2026 and up ~75% off the 2025 trough, but still well below the early-2025 peak. The move reflects growing confidence that the new management team's playbook — repricing higher, shedding unprofitable membership, and restoring margin discipline over membership growth — is working. Q1 2026 reinforced that view: all four segments beat internal plan, and management raised the full-year adjusted EPS outlook to >$18.25. Q2 is the test of whether that momentum is durable.
| Metric | Street Estimate | Q2 2025 Actual | Notes |
|---|---|---|---|
| Adjusted EPS | ~$4.84 (+18.5% YoY) | $4.08 (adj) | vs GAAP $3.74 last year |
| Total Revenue | ~$110.7B (~flat) | $111.6B | Membership shedding offsets pricing |
| Consolidated MCR | ~88.5% | 89.4% | Improvement is the whole thesis |
A key nuance: management guided to ~2/3 of full-year earnings landing in the first half. Against the >$18.25 full-year adjusted guide, that implies roughly $12.2B / ~$12.17 of H1 adjusted EPS, and with Q1 already at $7.23, an implied Q2 of ~$4.90–$4.95. Consensus at $4.84 sits modestly below the guidance-implied run-rate — setting a beatable bar if trend behaves.
This is the crux. In 2025, medical trend ran well ahead of pricing (MA trend ~7.5% vs. ~5% pricing), which broke the model. For 2026, UNH repriced MA to a ~10% trend assumption. On the Q1 call, management said utilization remained at 2025's elevated-but-stable levels with "modest favorability in government programs" and no inflection. The critical message investors want in Q2: is trend still tracking at or below pricing? Management flagged Q2 as "usually quite informative" for the full-year read — so this print carries more signal than most.
Don't panic at a rising MCR. Management explicitly guided that H1 MCR runs >250bps below the full-year midpoint and H2 runs >200bps above, driven by IRA-related Part D seasonality. So a jump from Q1's 83.9% to a Street-modeled ~88.5% in Q2 is expected mechanics, not deterioration. The question is whether the reported number lands in-line/better and whether underlying trend commentary stays benign.
Q1's beat was partly driven by ~$500M+ of net favorable prior-year development and management stressed they've kept a similarly conservative reserve posture. Days claims payable rose to 48.6 in Q1 (from 45.5 a year earlier) — a sign of building conservatism. Watch DCP and reserve development in Q2 to judge whether the beat is "clean" (operational) versus reserve-driven. A high-quality beat with maintained prudence is the bull case.
The epicenter of 2025's damage. Q1 2026 delivered $1.3B adjusted operating earnings (5.4% margin) — a meaningful step up — driven by clinical/medical management wins (e.g., ~35% fewer skilled-nursing admissions in a pilot region) and operating discipline. Management reiterated a long-term path to 6–8% margins, with improvement accelerating into 2027. But they warned Optum Health earnings moderate sharply after Q1 (majority of full-year earnings front-loaded), so Q2's absolute number will look smaller — focus on the year-over-year trajectory and progress on the ~$600M+ loss-contract (PDR) renegotiations/exits.
After raising to >$18.25 adjusted in Q1, the market will scrutinize whether management raises again, reaffirms, or signals conservatism. Given the deliberately "prudent" language in Q1, a reaffirm with beat-and-hold is the likely base case; another raise would be a strong positive surprise. Any hedging on H2 trend would be a red flag.
The bar is set for ~$4.84 EPS on ~$110.7B revenue with an ~88.5% MCR — a bar that sits slightly below the company's own guidance-implied run-rate, making a beat plausible if trend cooperates. But after two consecutive beat-and-raise quarters and a ~75% rally off the lows, expectations have re-rated meaningfully, so the reaction hinges less on the headline and more on quality:
Given Q2 is historically the most informative read on the full year — and management has flagged it as such — this print is likely the single most important checkpoint for validating (or puncturing) the turnaround narrative that has driven the stock's 2026 recovery.
Note: All figures are drawn from UNH's Q1 2026 and Q2 2025 earnings releases/calls and market data through July 15, 2026; consensus figures are as reported in pre-earnings news coverage and are approximate.